U
U. Nitz
Researcher at University of Düsseldorf
Publications - 99
Citations - 6427
U. Nitz is an academic researcher from University of Düsseldorf. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 14, co-authored 73 publications receiving 5826 citations. Previous affiliations of U. Nitz include Bethesda Hospital.
Papers
More filters
Journal ArticleDOI
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022.
Marc Thill,Diana Lüftner,Cornelia Kolberg-Liedtke,Ute-Susann Albert,Maggie Banys-Paluchowski,Ingo Bauerfeind,Jens-Uwe Blohmer,Wilfried Budach,Peter Dall,Eva M. Fallenberg,Peter A. Fasching,Tanja Fehm,Michael W. Friedrich,Bernd Gerber,Oleg Gluz,Nadia Harbeck,Jörg Heil,Jens Huober,Christian Jackisch,Hans Kreipe,David Krug,W. Kühn,Sherko Kümmel,Sibylle Loibl,Michael P. Lux,Nicolai Maass,Christoph Mundhenke,U. Nitz,Tjoung-Won Park-Simon,Toralf Reimer,Kerstin Rhiem,Achim Rody,Marcus Schmidt,Andreas Schneeweiss,F Schütz,Hans-Peter Sinn,Christine Solbach,Erich-Franz Solomayer,Elmar Stickeler,Christoph Thomssen,Michael Untch,Isabell Witzel,Achim Wöckel,Volkmar Müller,Wolfgang Janni,Nina Ditsch +45 more
TL;DR: The Breast Committee of the Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group, AGO) presents the 2022 update of the evidence-based recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer.
Journal ArticleDOI
AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022
Maggie Banys-Paluchowski,Marc Thill,W. Kühn,Nina Ditsch,Jörg Heil,Achim Wöckel,Eva M. Fallenberg,Michael W. Friedrich,Sherko Kümmel,Volkmar Müller,Wolfgang Janni,Ute-Susann Albert,Ingo Bauerfeind,Jens-Uwe Blohmer,Wilfried Budach,Peter Dall,Peter A. Fasching,Tanja Fehm,Oleg Gluz,Nadia Harbeck,Jens Huober,Christian Jackisch,Cornelia Kolberg-Liedtke,Hans Kreipe,David Krug,Sibylle Loibl,Diana Lüftner,Michael P. Lux,Nicolai Maass,Christoph Mundhenke,U. Nitz,Tjoung-Won Park-Simon,Toralf Reimer,Kerstin Rhiem,Achim Rody,Marcus Schmidt,Andreas Schneeweiss,F Schütz,H. Sinn,Christine Solbach,Erich-Franz Solomayer,Elmar Stickeler,Christoph Thomssen,Michael Untch,Isabell Witzel,Bernd Gerber +45 more
TL;DR: The recommendations of the AGO Breast Committee on the surgical therapy of breast cancer were last updated in March 2022 and the most important changes concern localization techniques, resection margins, axillary management in the neoadjuvant setting and the evaluation of the meshes in reconstructive surgery.
Proceedings ArticleDOI
Abstract P6-09-10: Results of multigene assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME decision impact study
Rachel Wuerstlein,O Gluz,R Kates,M. Persoon,M Wasmayr,Michael Knauer,R Koplmüller,E-M Grischke,Christian Schem,Marc Thill,S. Hasmueller,F Griesinger,A Koehler,Burkhard Otremba,Christian Schindlbeck,Toralf Reimer,J Krauter,Oliver Tomé,F Otto,K. Friedrichs,U-S Albert,Gerhard Gebauer,U. Nitz,Nadia Harbeck +23 more
TL;DR: In a decision impact study, the true percentage of CT saved by a prognostic test depends on cohort characteristics, and the WSG PRIME study showed that the 70-gene signature (MammaPrint) and the corresponding molecular subtype (BluePrint) strongly impacted clinical therapy decisions in EBC with up to 3 involved lymph nodes.
Journal ArticleDOI
LBA14 Impact of age, recurrence score (RS) and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Analysis of ADAPT and ADAPTcycle trials
Oleg Gluz,U. Nitz,Matthias Christgen,Sherko Kuemmel,Manfred Braun,M Thill,Bahriye Aktas,Pauline Wimberger,Kerstin Luedtke-Heckenkamp,Matthias Zaiss,Mathias Warm,Claudia Schumacher,Christian Schem,Monika Karla Graeser,Andreas D. Hartkopf,Ronald E. Kates,CZ Eulenburg,Peter Schmid,Hans Kreipe,Nadia Harbeck +19 more
TL;DR: In this article , the authors investigated the impact of age, RS, and OFS on ET response, in ADAPT and its validation in the first part of ongoing phase III AdAPTcycle trial, where patients were randomized to (neo)adjuvant CT or AI+ribociclib.
Journal Article
Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer
A. D. Bois,H.-J. Lück,Werner Meier,Volker Möbus,SD Costa,Barbara Richter,Thomas Bauknecht,M. Warm,W. Schroeder,S. Olbricht,U. Nitz,C. Jackisch +11 more
TL;DR: In this article, an interim analysis after 1 year's accrual to the prospectively randomized German Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) study is presented.